This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Krystal Biotech, Inc.
11/2/2026
Good morning and thank you for standing by and welcome to Crystal Biotech's third quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentations, there will be a question and answer session. During the question and answer session, there will be a limit of two questions per participant. As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Senior Vice President of Corporate Development. Please begin.
Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the third quarter of 2026. The press release is available on our website at www.crystalbio.com. We also filed our earnings 8K and 10Q with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer, Suma Krishnan, President of Research and Development, Laurent Goux, Executive Vice President and General Manager for Europe, Christine Wilson, Senior Vice President and Head of U.S. Commercial, and Kate Romano, Chief Accounting Officer. This conference call will, and our responses to questions may, contain forward-looking statements. Your caution not to rely on these forward-looking statements which are based on current expectations using the information available as of the date of this call and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC file. With that, I will turn the call over to Krish.
Good morning, and thank you for joining us. Q3 was another strong Q for Crystal. We delivered $127.3 million in Visevic revenue, an increase of 30% from the same period last year, and reported diluted earnings of $2.05 a share, and ended September with $1.2 billion in cash and investments. Those results, they reflect a business that's growing, that's profitable, and generating the resources to advance our pipeline. They also reflect the work our teams have done to build Crystal into a global company with commercial operations, manufacturing capabilities, clinical development programs that we own and control. And today, we have generated approximately $1.1 billion in ViseVec revenue since launch, and that is an important milestone for a medicine developed here at Crystal. Behind that number are so many patients receiving treatment physicians incorporating a new paradigm of genetic medicines into their practices and families getting access to a medicine that addresses the underlying cause of DEB. In the U.S., demand continues to grow, as does the prescribing physician base. And internationally, we continue to translate physician interest into patients' thoughts across Germany, France, and Japan. The pricing secured for Vajavec in Japan and Germany and Italy today reflects recognition of the meaningful benefits that Vajavec provides patients and families. I'm proud of our team's thoughtful work to demonstrate that value and establish a strong foundation for patient access internationally. We'll continue to build on this progress in ensuing pricing discussions across additional markets, and Laurent will discuss those markets in more detail. We also made meaningful progress in development. We were really encouraged by the recent Golan Syndrome Day clinical results that demonstrated regression in both injected and non-injected lesions together with the histologically confirmed clearance of an injected lesion in each patient. So that gives us a very strong foundation to have conversations with the FDA on next steps. I want to address the updated timing of some of our clinical readouts and while we had hoped to share these readouts sooner, I want to be clear that the programs continue to progress well, and we look forward to sharing results in the upcoming months. Suma will elaborate more in a few minutes. Alongside these developments, our board authorized a share repurchase program of up to $400 million that we expect to deploy over the next two years. We have reached a position where our financial resources allow us to support global commercial expansion, pipeline and clinical development, and have the flexibility to return capital to shareholders. And the authorization reflects our confidence in Crystal's long-term prospects and our responsibility to allocate this capital thoughtfully. So taken all together, this queue demonstrated the strength of the business we've built. It demonstrated continued commercial growth, substantial profitability and progress across the pipeline. For that, I'd like to thank our employees, our investigators, and the patients and families participating in our studies for helping make that progress possible. And with that, I'll turn it over to our team to work through commercial, clinical and financial updates.
You're reading a preview of the KRYS Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing